Close Menu

NEW YORK – In Adaptive Biotechnologies' first ever quarterly results conference call, officials unveiled plans for new products and regulatory approvals.

The Seattle-based immune sequencing firm is developing new research and clinical assays — including a new research-use-only kit and a blood-based diagnostic test dubbed "immunoSeq Dx" — and is pursuing additional regulatory approvals for its existing clinical test, clonoSeq.

Adaptive officials also painted a promising picture of payor coverage for clonoSeq.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.